EuropaBio

European Healthcare calls for balanced, transparent funding of pharmacovigilance system

Monday, February 24, 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic medicines Association (EGA), the European biotech industry (EuropaBio), the Association of the European Self-Medication Industry (AESGP) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) support the implementation of an effective pharmacovigilance system to ensure patient safety and recognize recent efforts which have been made to ensure greater fairness, proportionality and transparency in some aspects of the proposals for the mechanism of fees to be paid to the EMA for these pharmacovigilance activities. Notably the industry welcomes the improvements regarding the annual fee to be paid by the Marketing Authorization Holders to the EMA. 

[Read More]

Industry responds to European clinical trials regulation revision

Monday, December 2, 2013

There is an increasing international competition in clinical trials because clinical research creates jobs, drives academic excellence and delivers innovative medicines for patients. Improving the attractiveness and competitiveness of Europe as a prime location for clinical research was a key driver for the revision of the E.U. clinical trial legislation, which aimed to reduce unnecessary red tape whilst preserving the quality and safety of clinical trials.

[Read More]